On April 1, 2024 RS Oncology reported two abstracts with comprehensive preclinical and translational data in support of their lead clinical oncology compound RSO-021, have been accepted for poster presentations at the Annual Meeting of the American Association for Cancer Research (AACR) (Free AACR Whitepaper), taking place April 5-10, 2024 in San Diego (Press release, RS Oncology, APR 1, 2024, View Source [SID1234641659]). RSO-021 is a first-in-class peroxiredoxin 3 (PRX3) covalent inhibitor that disables a critical antioxidant defense system in the mitochondria of tumor cells. Results from the completed Phase 1 clinical trial (clinical trials.gov #NCT05278975) will be an oral presentation on June 3rd, at the upcoming ASCO (Free ASCO Whitepaper) meeting in Chicago. Currently patients are being recruited to the Phase 2 dose expansion cohorts of the MITOPE clinical trial.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Covalent inactivation of PRX3 by RSO-021 represents a viable anticancer approach by targeting a universal tumor vulnerability of oxidative stress. The results we present at the AACR (Free AACR Whitepaper) Annual Meeting will highlight fundamental tumor cell features that are exploitable by this novel treatment." said Brian Cunniff, Chief Scientific Officer of RS Oncology.
Approximately 90% of mesotheliomas and 15-20% of solid tumors present with malignant pleural effusion (MPE) at late stage leaving the patients with poor prognoses and limited options. RSO-021 is a local therapy for patients with MPE arising from mesothelioma or advanced metastatic tumors. "The discoveries presented at AACR (Free AACR Whitepaper) highlight tumor cell features that are associated with sensitivity to RSO-021, providing a potential strategy to maximize patient response to RSO-021", added George Naumov, Chief Operations Officer of RS Oncology.
Details of the poster presentations:
Title: First-in-class peroxiredoxin 3 (PRX3) inhibitor RSO-021 triggers mesenchymal-to-epithelial transition in mesothelioma
Presenter: Brian Cunniff, CSO of RS Oncology
Session Category and Title: Experimental and Molecular Therapeutics – Other Cellular Mechanisms for Anticancer Drug Action
Session Date and Time: Tuesday Apr 9, 2024 9:00 AM – 12:30 PM
Location: Poster Section 29
Abstract Number: 4716
Title: SLC7A11 modulates sensitivity to the first-in-class mitochondrial peroxiredoxin 3 inhibitor thiostrepton (RSO-021) via a ferroptosis independent pathway
Presenter: Brian Cunniff, CSO of RS Oncology
Session Category and Title: Molecular/Cellular Biology and Genetics- Cellular Stress Responses 1
Session Date and Time: Sunday Apr 7, 2024 1:30 PM – 5:00 PM
Location: Poster Section 16
Published Abstract Number: 384
The full abstracts will be published on March 22, 2024, in an online-only proceedings supplement to the AACR (Free AACR Whitepaper) journal, Cancer Research.